ArticleIn vivo (Athens, Greece)
Signal Detection Analysis of Hypnotic-induced Respiratory Depression.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimBenzodiazepine receptor agonists (BZRAs) are well-known hypnotics. Although the research is scarce, relatively newer hypnotics such as melatonin receptor agonists (MRAs) and dual orexin receptor antagonists (DORAs), can be associated with respiratory depression. The association between hypnotic use and respiratory depression in clinical practice was investigated in this study. PATIENTS AND
methodsA total of 733,296 reports from the Japanese Adverse Event Reporting Database published between April 2004 and September 2023 were analyzed. The reporting odds ratios (RORs) and 95% confidence intervals (CIs) for respiratory depression associated with each hypnotic condition were calculated after adjusting for potential confounders.
resultsAmong all the reports, 5,147 involved respiratory depression. After adjustments for sex, age, reporting year, concomitant medications, and medical history the associations with non-benzodiazepines (adjusted ROR=1.06; 95% CI=0.92-1.23) and DORAs (adjusted ROR=0.94; 95% CI=0.70-1.27) were not significant. In contrast, significant associations remained for BZRAs (adjusted ROR=1.34; 95% CI=1.20-1.49) and MRAs (adjusted ROR=2.03; 95% CI=1.56-2.64). The stratified analyses showed that BZRAs were associated with respiratory depression regardless of age, whereas MRAs were associated regardless of opioid use.
conclusionThe associations between hypnotics and respiratory depression varied depending on the drug administered. In addition to BZRAs, MRAs may also have a potential risk for respiratory depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.